Ningbo TeYi Secures Tens of Millions in Series A Funding Led by Mifang Capital to Build a Personalized Chronic Disease Nutrition Management Platform

VCBeat (WeChat: vcbeat) has learned that Ningbo Teyi Food Co., Ltd. (“Ningbo Teyi”) recently announced the completion of a tens-of-millions-yuan Series A financing round, led by Mifang Capital. It is reported that following this round of financing, Ningbo Teyi will continue to expand and enrich its product portfolio in the field of adult special diseases, enhance its brand influence, and strive to build a leading enterprise-level platform for personalized nutritional dietary solutions for chronic disease management.

Ningbo Teyi is an innovative high-tech company in China dedicated to the research, development, and production of foods for special medical purposes (FSMP). With FSMP products at its core, the company provides personalized nutritional therapy guidance solutions for specific populations.

Foods for Special Medical Purposes (FSMP) are a category of specially formulated foods, professionally processed and prepared to meet the specific nutritional or dietary needs of individuals with restricted food intake, digestive or absorptive impairments, metabolic disorders, or specific disease states. According to statistics from the China Health Food Association, the global annual consumption of FSMP totals between RMB 56 billion and RMB 64 billion, with the market size growing at an annual rate of 6%. In the United States, 65% of malnourished patients use FSMP, compared to 27% in the United Kingdom, while in China, the figure stands at only 1.6%, indicating that FSMP in China falls far short of meeting market demand.

It is reported that Ningbo Teyi possesses a first-class automated production base with high standards, compliant with national quality and registration requirements. The company offers a diverse product portfolio and has currently launched nutritional dietary management solutions for chronic conditions in areas such as infant cow’s milk protein allergy, lactose intolerance, prematurity/low birth weight, diabetes, COPD, postoperative recovery, and oncology. Notably, Ningbo Teyi is one of the earliest companies in China to engage in the research and development, production, and sales of specialized medical foods for infants.

Regarding the team, Mr. Yang Guomin, founder of Ningbo Teyi, previously worked for world-renowned healthcare companies (including Fresenius, Edwards, and Novartis Pharmaceuticals), accumulating over 15 years of experience in sales, government affairs, and market access. Furthermore, the company’s management team has served for many years at prestigious global pharmaceutical corporations, bringing extensive expertise in pharmaceutical manufacturing, marketing, and commercialization. In addition, under the leadership of scientists from DSM’s Asia-Pacific R&D Center, the company has established a specialized R&D team focused on foods for special medical purposes (FSMP). To date, Ningbo Teyi has built a professional promotional team covering nearly 30 provinces across East, Central, South, North, and West China.

Mr. Yang Guomin, founder of Ningbo Teyi, stated that the market for foods for special medical purposes has long been dominated by foreign brands. As one of the earliest enterprises in China to prioritize independent technological R&D and establish Chinese proprietary brands, Ningbo Teyi’s team holds a strong commitment to self-driven innovation and stringent quality control. Mr. Yang expressed great pleasure in partnering with Mifang Capital, a leading domestic healthcare investment institution, noting that both parties share a highly aligned vision for industry development.